Chinook Therapeutics, Inc. (KDNY) Financial Statements (2024 and earlier)

Company Profile

Business Address 400 FAIRVIEW AVENUE NORTH, SUITE 900
SEATTLE, WA 98109
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments378,325286,837247,372213,602266,439326,103
Cash and cash equivalents115,438181,724187,75059,624126,310157,614
Short-term investments262,887105,11359,622153,978140,129168,489
Receivables1,09110,06126234212,037989
Other undisclosed current assets6,1763,7416,4473,9584,50023,039
Total current assets:385,592300,639254,081217,902282,976350,131
Noncurrent Assets
Operating lease, right-of-use asset48,97055,38555,67321,110
Property, plant and equipment16,90818,93520,62624,68829,15731,085
Long-term investments and receivables11,06076,4203,000 11,43423,614
Long-term investments11,06076,4203,000 11,43423,614
Intangible assets, net (including goodwill)60,95462,67689,43227,14533,46939,830
Goodwill11711722,4418,1678,3348,723
Intangible assets, net (excluding goodwill)60,83762,55966,99118,97825,13531,107
Restricted cash and investments2,0742,0741,750468468468
Other noncurrent assets7,3266,4744,440   
Other undisclosed noncurrent assets41,20041,200    
Total noncurrent assets:188,492263,164174,92173,41174,52894,997
TOTAL ASSETS:574,084563,803429,002291,313357,504445,128
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities20,85715,3754,2077,6749,3629,198
Employee-related liabilities6,455 3,6774,6195,320
Accounts payable9,7518,5803,9954141,4571,150
Accrued liabilities11,1063402123,5833,2862,728
Deferred revenue   956,950
Debt    1,803  
Deferred rent credit     653
Business combination, contingent consideration, liability      6,829
Deferred revenue and credits14,923
Due to related parties   9   
Contract with customer, liability16,000
Other undisclosed current liabilities29,97824,71018,4985,1744,50210,451
Total current liabilities:50,83540,08522,80921,60130,51741,401
Noncurrent Liabilities
Long-term debt and lease obligation:  39,58938,70931,636  
Liabilities, other than long-term debt43,9905,89519,082168,954191,676166,254
Deferred revenue and credits158,139
Deferred revenue    166,963
Contract with customer, liability172,671
Deferred rent credit     11,063
Deferred tax liabilities, net6,1046,538
Deferred income tax liabilities5,07673516,377 
Other liabilities   905940840818
Operating lease, liability34,49439,58938,70931,636
Business combination, contingent consideration, liability4,4205,1601,8001,051998759
Other undisclosed noncurrent liabilities37,31824,59113,7803,527  
Total noncurrent liabilities:81,30870,07571,571204,117191,676166,254
Total liabilities:132,143110,16094,380225,718222,193207,655
Equity
Equity, attributable to parent441,941453,643334,62265,595135,311237,473
Common stock754888
Additional paid in capital864,729685,459463,436552,077538,895519,435
Accumulated other comprehensive income (loss)(3,164)(55)114149401,893
Accumulated deficit(419,631)(231,766)(128,829)(486,904)(404,532)(283,863)
Total equity:441,941453,643334,62265,595135,311237,473
TOTAL LIABILITIES AND EQUITY:574,084563,803429,002291,313357,504445,128

Income Statement (P&L) ($ in thousands)

6/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues6,12851,62525,50017,25815,08717,239
Revenue, net17,239
Sublease income   25,500 
Gross profit:6,12851,62525,50017,25815,08717,239
Operating expenses(177,502)(121,659)(57,054)(107,400)(116,447)(123,692)
Other undisclosed operating loss(13,709)(29,004)(24,673)   
Operating loss:(185,083)(99,038)(56,227)(90,142)(101,360)(106,453)
Nonoperating income (expense)4,809(170)3135,3585,2203,226
Investment income, nonoperating4,809  5,4515,2843,444
Other nonoperating income (expense) (170)313(93)(64)(218)
Interest and debt expense   (15)   
Loss from continuing operations before equity method investments, income taxes:(180,274)(99,208)(55,929)(84,784)(96,140)(103,227)
Loss from equity method investments(3,250)(1,636)    
Other undisclosed loss from continuing operations before income taxes   (27,696)   
Loss from continuing operations before income taxes:(183,524)(100,844)(83,625)(84,784)(96,140)(103,227)
Income tax expense (benefit) (4,341)(2,093)2,0032,41278311,364
Other undisclosed loss from continuing operations      
Loss from continuing operations:(187,865)(102,937)(81,622)(82,372)(95,357)(91,863)
Loss before gain (loss) on sale of properties:(102,937)(81,622)(82,372)(95,357)(91,863)
Net loss available to common stockholders, diluted:(187,865)(102,937)(81,622)(82,372)(95,357)(91,863)

Comprehensive Income ($ in thousands)

6/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(187,865)(102,937)(81,622)(82,372)(95,357)(91,863)
Other comprehensive income (loss)(3,109)(66)18(526)(953)3,577
Other undisclosed comprehensive loss      
Comprehensive loss:(190,974)(103,003)(81,604)(82,898)(96,310)(88,286)
Other undisclosed comprehensive income, net of tax, attributable to parent      
Comprehensive loss, net of tax, attributable to parent:(190,974)(103,003)(81,604)(82,898)(96,310)(88,286)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: